Pfizer Faces Italian Antitrust Probe Over Xalatan Patent
L’Autorita Garante della Concorrenza e del Mercato revealed the probe Tuesday with surprise inspections at the headquarters of Pfizer's Italian unit following a complaint from Ratiopharm, a major European generic-drug maker.
According to the complaint, Pfizer Italia SRL took a number of steps to keep generic versions of Xalatan off the Italian market, including fraudulently seeking an extension...
Already a subscriber? Click here to login